{"name":"Apogee Therapeutics, Inc.","slug":"apogee-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APG777","genericName":"APG777","slug":"apg777","indication":"Solid tumors with FGFR alterations","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"APG990","genericName":"APG990","slug":"apg990","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"APG777","genericName":"APG777","slug":"apg777","phase":"phase_2","mechanism":"APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3.","indications":["Solid tumors with FGFR alterations"],"catalyst":""},{"name":"APG990","genericName":"APG990","slug":"apg990","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"pipeline","source":"The Manila Times","summary":"Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times","headline":"Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQaTh3cGhEZDFVN0Jvd3pzUjdlbDhicjBkLXRzLTR5eUhFcVMtajhyNVh6WFdEaTFSWnc3OXB2aDNWXzAyRjFmZ05uRWlWXzFSb3J6TlNXNmdwcWRhWVpQRVVjMkdVVDNvck5pdjB6UnBkM0dMR200RGhaR1dtTWhEWXRjdENYVGpPOW9QMkhVaGVrSXJ1WGNhVGhiSUE0Q3NaN0owakhwQzZ6TW1TdDBJcGVmUlBnQ0tiWlV6OThkQmNObmMwUWlpZGJ0RzJ2ZTJqNXMyXzBITy10cDR2azRfM3ppQzQ?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - The Globe and Mail","headline":"APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE0tWU5WaURRRnNWMlNlVEZxWnNPLTJGV1JBT3NnREZmVU1qNVZ4RnVVeU9QUEZicHFHeElBSVE2Wkl0bGwxc0FmcHpGdlBQRHQyaDdCYTBhTkFrdTN1Y2x5ZmdGdW42OHPSAWdBVV95cUxNLVlOVmlEUUZzVjJTZVRGcVpzTy0yRldSQU9zZ0RGZlVNajVWeEZ1VXlPUFBGYnBxR3hJQUlRNlpJdGxsMXNBZnB6RnZQUER0Mmg3QmEwYU5Ba3UzdWNseWZnRnVuNjhz?oc=5","date":"2026-03-24","type":"pipeline","source":"Bitget","summary":"APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks - Bitget","headline":"APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPV3djN1J4M1VUbmpiWVQ1TEdSUUl0S1BzaGdheUNERHA3eF9XRk9kNzhxR0k3UW1Vd2E5OUdLYlJ0TmRlLUdjN05OMXVzM1oyM205Z3FiZW5TYTRBZkVLbFp3S2NQaTVFTUp1Ml90cjcxX3FlRWlicG1hUzVnQUIwNWdINlo?oc=5","date":"2026-03-23","type":"pipeline","source":"StocksToTrade","summary":"Apogee Therapeutics Sees Price Target Boost Amid Clinical Progress - StocksToTrade","headline":"Apogee Therapeutics Sees Price Target Boost Amid Clinical Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPd2p4RHowNHR3Y3VRTVJRLXE4VnhTN2hZZFBBUGV4RjFsUXp0UlZXQ3d4V2hyM2xFM1FEeWx2Z1FaTWVBV2k5SjVneGVGbVg3cFowMzlwRklPMDZSS01pTWJiQUE5TkRqcUN5emdzSjdXUnFwZlB1ZG80cllvdGpUMTBYenRWN0EtV1VWUUlnbDV6VVdBTlNWcg?oc=5","date":"2026-02-16","type":"pipeline","source":"Financial Times","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight – Company Announcement - FT.com - Financial Times","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wWmJXaDdZNzY3b0ZldjhTSENlWGNtSGZtbjgyNElwMzZ5c1N5MGpGb1hlMDFia05mU19oMG45bXN0OEdIa0tKRFF6WXA1R21CdmdfSXB3?oc=5","date":"2026-02-14","type":"pipeline","source":"Stock Titan","summary":"APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan","headline":"APGE Financials: Income Statement, Balance Sheet & Cash Flow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQLUQ1OE55Mk9aVVkycjFzRXE0dXNPVFVxbk9iYU9vdGFQQnp5Rk0zVFNucVlfUkxLc3FzVHBxT1RDYUl6cExZbjlOaGNhMlloaWEyVXRCM2M3V2lfYncyUk55b1RWNVhnb1UtTjBodU5wZ0lIX3VLNTU1a0JiZUZ5TkJDcFJfeXNubDZHMklTNWYxQlNRWlFZ?oc=5","date":"2026-01-15","type":"deal","source":"BioWorld News","summary":"Muted and missing M&As: JPM deals absent in 2026 - BioWorld News","headline":"Muted and missing M&As: JPM deals absent in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNVVJLOGktcUxjTFRPQkxlNlM1NHVtOTBZUFR1UGdSRERxZ3hxTG9qMS1hTF9idU1tRXR1aE44RGhUeUdab2JWM0ZmMUNwNmE5anNMR3RBWVdzLXpMa0llVzliQXhwMjFNVnBwZVB3TTZwT09LQ0FNYUM5SjBzZWpVc1pWdHl5Y2FKVFFRSEtZZ2kwTHVxSjFveXpSbnA0ZDdCbkZtemN4NEVad0xNdWUwd2JScw?oc=5","date":"2026-01-02","type":"pipeline","source":"Kalkine Media","summary":"Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media","headline":"Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN2Q4bUd5RWFzeTV1ZXdXRHo2aVBqd3RoRFRBeF91MUR2aWNNdWRTbkwwZ3d1cFdka0JzWTNGS01NQ3RXZVAtaG9WRnV4QnFDQWswRTdrZENyQVdXSTJxWS1EZ0tDWVVyLXhaRklQeHhUQmpsbTZaNUlCNzgteWxuSXNVZmJlMW1MRkRsODlFNFdBNDluUDZJdDZtdUZjblNzcDk2RHJxR29xZw?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace","headline":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcU9mRnNHcXZKTnNONUJJcDNaaXp3MkVHUEFVSG1SUkhyYmQwSFhMVjh3RHhUNEJSNDRES3poNG03QThPVHF0dXJBeWJEUjlBbkctWVhCR3RKOHFmaDFyMDNGdTZGdmRzRkxBNlRkRWw4SVhjUUFaNnJUVlM2S3VyZXVwenZMUklGYlF5dUNMSnlwOTdDeW9GNkNiZlJ2eU53YnN3YVNtMUZfZktFZE9HVURTVkJCbDg3NUxVSQ?oc=5","date":"2025-10-30","type":"pipeline","source":"Seeking Alpha","summary":"Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE) - Seeking Alpha","headline":"Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNajEtWldZY3VUczVMSmhkbld1TFBWWkVhbEd4MzVRSm1pdUNZeVlacEhhdTJWeWlZaXpBWEx0NmVuOWtoV3paVkRSUEU4NGhxQUp6Z2h1UWdKSXZvdlhtX0J0UFRxclBaZGNfdW9Wb1pSeGRoRllHb1F1RFd1Sm1SaHhFeFIzcWtUOU1lZURSdVNTVTFmQjVsaQ?oc=5","date":"2025-07-07","type":"trial","source":"BioPharma Dive","summary":"Apogee touts positive data for atopic dermatitis drug - BioPharma Dive","headline":"Apogee touts positive data for atopic dermatitis drug","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}